Medtronic (MDT) Tops Q4 EPS by 1c; offers 2025 guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Medtronic (MDT) Tops Q4 EPS by 1c; offers 2025 guidance
May 24, 2024 6:16 AM EDT
RBC Capital analyst Shagun Singh reiterated a Sector Perform rating and $92.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "MDT delivered a beat (upside surprise of 1.7%/0.7% on sales/EPS, respectively), but FY25 guidance was in-line and FQ1 modestly below, sending... More
May 24, 2024 5:20 AM EDT
Wells Fargo analyst Larry Biegelsen raised the price target on Medtronic, Inc. (NYSE: MDT) to $105.00 (from $102.00) while maintaining a Overweight rating.
The analyst comments "Strong FQ4 rev beat, but elevated opex drives muted EPS beat. MDT reported FQ4 2024 rev of $8.59B (+5.4% organic)... More
May 24, 2024 4:59 AM EDT
UBS analyst Danielle Antalffy raised the price target on Medtronic, Inc. (NYSE: MDT) to $76.00 (from $75.00) while maintaining a Sell rating.
The analyst comments "Despite Outperformance, We Remain Skeptical of Sustainability of New Product Momentum; Commentary Suggests FY25 Consensus EPS Possibly... More
May 23, 2024 4:25 PM EDT
Stifel analyst Rick Wise reiterated a Buy rating and $100.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "Notching a sixth consecutive mid-single-digit top-line revenue growth quarter (+5.4% organic), Medtronics 18 months of more-consistent performance positively suggest stable underlying business fundamentals. Now starting FY2025... More
May 23, 2024 4:15 PM EDT
BTIG analyst Sean Lavin reiterated a Neutral rating on Medtronic, Inc. (NYSE: MDT).
The analyst comments "We maintain our Neutral rating following FY4Q24 results. MDT reported rev. of $8.589B (0.5% Y/Y, 5.4% organic) and adj. EPS of $1.46 (-7% Y/Y), above BTIG/Consensus ests. of $8.443B/$8.445B and adj. EPS of $1.46/$1.45 by ~1.7% and ~0.6% respectively. Segment performance was favorable in Neuroscience (3.6% vs. Cons), Medical-Surgical (1.1% vs. Cons), and Diabetes (+0.9% vs. Cons)... More
